Skip to main content
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · INO ISIN · US45773H4092 LEI · 529900B9W875XDZXTM97 US Manufacturing
Open in API
Filings indexed 1,003 across all filing types
Latest filing 2024-08-13 Capital/Financing Update
Country US United States of America
Listing US INO

About INOVIO PHARMACEUTICALS, INC.

https://www.inovio.com/

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines. The company's core technology centers on designing proprietary DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific, targeted proteins to combat disease. These DNA medicines are delivered into cells using the company's proprietary investigational CELLECTRA® smart devices. This platform is designed to enable in vivo protein production and achieve therapeutic effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. The company's development pipeline targets HPV-related diseases, various cancers, and infectious diseases.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 13, 2024, by Inovio Pharmaceuticals, Inc. It announces the entry into a material definitive agreement, specifically an Equity Distribution Agreement with a sales agent for an at-the-market offering of common stock up to $60 million. The document includes details about the agreement, commission, and indemnification rights, and references exhibits including the full agreement and legal opinion. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance report. The primary content is an announcement of a financing arrangement and capital raising activity. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is 5548 characters, sufficient to contain substantive details about the financing agreement rather than a brief announcement or a report publication notice. Confidence is high due to clear identification of the nature of the filing and its content.
2024-08-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, by Inovio Pharmaceuticals, Inc. It announces the issuance of a press release containing financial results for the quarter and six months ended June 30, 2024. The text explicitly states that the press release is furnished as an exhibit and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3591 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories like Earnings Release (ER) or Interim Report (IR) because it only references the press release without including the financial data itself.
2024-08-08 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
FORM 4
Director's Dealing
2024-07-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Inovio Pharmaceuticals, Inc. It includes two main items: Item 5.02, which details the granting of performance-based restricted stock units (PSU Awards) to named executive officers, indicating changes in compensatory arrangements for certain officers; and Item 5.07, which reports the submission of matters to a vote of security holders at the 2024 Annual Meeting of Stockholders, including detailed voting results for director elections, auditor ratification, and advisory approval of executive compensation. The presence of detailed voting results from the Annual Meeting clearly identifies this as a Declaration of Voting Results document. The document is over 11,000 characters, so it is not a mere announcement or report publication notice. It is not an annual report, earnings release, or management discussion. The focus on voting outcomes at the Annual Meeting aligns with the category Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the correct classification is DVA with high confidence.
2024-05-28 English
FORM 4
Director's Dealing
2024-05-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.